GlassScriptPhysician profile
Jasmine Gowarty
NPI 1003263732
$3,497.59
in general payments reported to CMS, 2019-2025
35 companies · $2,536 in 2025
The $2,536 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.61 · 2021: $24.73 · 2022: $44.71 · 2023: $267 · 2024: $612 · 2025: $2,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528 · Long Term Medical Supply Or Device Loan: $698 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.65 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $868.83 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $232.39 | 2024-2025 | Xpovio |
| Glaxosmithkline, LLC. | $197.80 | 2024-2025 | Ojjaara, Blenrep |
| Gilead Sciences, INC. | $188.11 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $179.36 | 2024-2025 | Opdualag, Opdivo |
| Medtronic, INC. | $153.05 | 2024-2025 | Osteocool Rf Ablation System |
| Celgene Corporation | $149.30 | 2023-2025 | Reblozyl, Pomalyst |
| Sirtex Medical INC | $142.16 | 2024 | Sir-Spheres Microspheres |
| Mirati Therapeutics, INC. | $115.09 | 2023 | Krazati |
| Exelixis INC. | $114.40 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $104.06 | 2024-2025 | Enhertu |
| Pfizer INC. | $100.25 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Merck Sharp & Dohme LLC | $83.83 | 2022-2025 | Keytruda, Dificid, Zerbaxa |
| Genzyme Corporation | $82.81 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $74.15 | 2025 | |
| Genentech USA, INC. | $70.69 | 2025 | Tecentriq, Itovebi |
| Lilly USA, LLC | $66.93 | 2025 | Jaypirca, Verzenio, Retevmo |
| Tempus Ai, INC | $66.44 | 2024 | |
| Janssen Biotech, INC. | $54.92 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Astellas Pharma US INC | $43.26 | 2025 | Vyloy, Xospata |
| Taiho Oncology, INC. | $35.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.32 | 2025 | Ninlaro |
| Genmab U.S., INC. | $29.18 | 2025 | Epkinly |
| Stemline Therapeutics INC. | $26.45 | 2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $23.49 | 2022 | |
| Array Biopharma INC | $23.25 | 2025 | Braftovi, Lorbrena, Xalkori |
| Deciphera Pharmaceuticals INC. | $22.52 | 2025 | Qinlock, Tgct |
| Bayer Healthcare Pharmaceuticals INC. | $20.97 | 2025 | |
| Ferring Pharmaceuticals INC. | $20.18 | 2025 | Adstiladrin |
| Regeneron Healthcare Solutions, INC. | $18.02 | 2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $17.44 | 2025 | Ultomiris |
| Emd Serono, INC. | $16.66 | 2023 | Bavencio |
| Caris Mpi, INC. | $14.68 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $13.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Gowarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.